This is multicenter, prospective, open label, non-interventional study that will collect real-world data (RWD) on the clinical efficacy and safety of NalIriFOx as a first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
Inclusion Criteria:
Exclusion Criteria:
i_mitrentsi@hecog.ondsl.gr+30 2106912520 ext. 24
mPDAC patients receiving NalIriFox as a first line therapy
m_moschoni@hecog.ondsl.gr+30 2106912520 ext. 12
Athens, 124 62, Greece
ikotsantis@gmail.com+30 21 0583 1000
fotis_tzoudas@hotmail.com+30 21 0350 1500
grigakos@oncologists.gr+30 21 0686 7000
astrimpakos@hygeia.gr+30 21 0686 7000
goik77@yahoo.com+30 21 0480 9000
mgkotzamanidou@yahoo.com+30 2132089511
thankotsakis@hotmail.com+30 2413502124
athinachristo@hotmail.com+30 261 360 1000
elenafou@gmail.com+30 231 330 7000